Galantamine: A Review Update
Abstract
Galantamine, like nor-belladine, is a benzazepine. Galanthus and other plants of the Amaryllidaceae are the most common sources of it. Galantamine is used to combat the muscle effects of gallamine triethiodide and tubocurarine by acting as a cholinesterase inhibitor. The review reveals the protective effects of galantamine on the functions and integrity of the liver, brain and memory impairment. Various independent studies have shown anti-Alzheimer, antioxidant, antidiabetic and neuroprotective effect of galantamine. The current review highlights current knowledge and the health-promoting effects of a drug known as galantamine. This review summarizes the current state in the pharmacology of galantamine, focusing on its effects on tolerance, dosage, drug interactions and pharmacological studies in animal models.
Keywords: Galantamine, Pharmacology, Acetylcholinesterase inhibitor, Neuroprotective, Protective effect.
Keywords:
Galantamine, Pharmacology, Acetylcholinesterase inhibitor, Neuroprotective, Protective effectDOI
https://doi.org/10.22270/jddt.v12i4.5426References
Upadhyay SD, Ahmad Y, Kohli S. A Review on Pharmacological Potential of Galantamine. Pharmacogn Commun. 2020; 10(2):63-6. https://doi.org/10.5530/pc.2020.2.13
Zarotsky V, Sramek JJ, Cutler NR. Galantamine hydrobromide: An agent for Alzheimer's disease. Am J Heal Pharm. 2003; 60(5):446-52. https://doi.org/10.1093/ajhp/60.5.446
Loy C, Schneider L. Galantamine for Alzheimer ' s disease ( Review ). Cochrane Libr. 2005; (4):345-54. https://doi.org/10.1002/14651858.CD001747.pub2
Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, et al. APP mouse models for Alzheimer's disease preclinical studies. EMBO J. 2017; 36(17):2473-87. https://doi.org/10.15252/embj.201797397
Sperling R, Mormino E, Johnson K. Perspective The Evolution of Preclinical Alzheimer ' s Disease : Implications for Prevention Trials. Neuron [Internet]. 2014; 84(3):608-22. https://doi.org/10.1016/j.neuron.2014.10.038
Tariot P. Current status and new developments with galantamine in the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2001; 2(12):2027-49. https://doi.org/10.1517/14656566.2.12.2027
Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bull. 2005; 64(6):519-24. https://doi.org/10.1016/j.brainresbull.2004.11.002
Satapathy SK, Ochani M, Dancho M, Hudson LK, Rosas-Ballina M, Valdes-Ferrer SI, et al. Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol Med. 2011; 17(7-8):599-606. https://doi.org/10.2119/molmed.2011.00083
Ali MA, El-Abhar HS, Kamel MA, Attia AS. Antidiabetic effect of galantamine: Novel effect for a known centrally acting drug. PLoS One. 2015; 10(8):1-28. https://doi.org/10.1371/journal.pone.0134648
Melo JB, Sousa C, Garção P, Oliveira CR, Agostinho P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci. 2009; 29(3):455-64. https://doi.org/10.1111/j.1460-9568.2009.06612.x
Halpin CM, Reilly C, Walsh JJ. Nature's anti-Alzheimer's drug: Isolation and structure elucidation of galantamine from Leucojum aestivum. J Chem Educ. 2010; 87(11):1242-3. https://doi.org/10.1021/ed100388x
Inden M, Takata K, Yanagisawa D, Ashihara E, Tooyama I, Shimohama S, et al. Α4 Nicotinic Acetylcholine Receptor Modulated By Galantamine on Nigrostriatal Terminals Regulates Dopamine Receptor-Mediated Rotational Behavior. Neurochem Int [Internet]. 2016; 94:74-81. https://doi.org/10.1016/j.neuint.2016.02.008
Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T. Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther. 2004; 310(3):933-42. https://doi.org/10.1124/jpet.104.067603
Marco-Contelles J, Rodríguez C, García AG. Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer's disease. Expert Opin Ther Pat. 2005; 15(5):575-87. https://doi.org/10.1517/13543776.15.5.575
Kausar S, Mustafa HG, Altaf AA, Mustafa G. Samia Kausar, Huda Ghulam Mustafa, Ataf Ali Altaf, and Ghulam Mustafa , Department of Chemistry, University of Gujrat, Gujrat, Pakistan Amin Badshah , Department of Chemistry, Quaid-i-Azam University, Islamabad, Pakistan © 2019. 2019; (October):1-12.
Bastida J, Berkov S, Torras Clavería L, Pigni NB, Andradre JP De, Martínez V, et al. Chemical and biological aspects of Amaryllidaceae alkaloids [Internet]. Vol. 661, Recent Advances in Pharmaceutical Sciences. 2011. 65-100 p. Available from: http://diposit.ub.edu/dspace/handle/2445/21374
Barton DHR, Kirby GW. 153. Phenol oxidation and biosynthesis. Part V. The synthesis of galanthamine. J Chem Soc. 1962; VI:806-17. https://doi.org/10.1039/jr9620000806
Barton DHR, 0' Brien RE, Sternhell S. Barton, 0' Brien, and Sternhell A New Reaction of hydrazone. J Chem Soc. 1962; (470):470-6. https://doi.org/10.1039/jr9620000470
Oliver*' DW, Dekkerl TG, Snyckers FO. Synthesis and pharmacology. Eur J Med Chem. 1991; 26:375-9. https://doi.org/10.1016/0223-5234(91)90097-7
Pilger C, Westermann B, Florke U, Fels G. A new stereoselective approach towards the galanthamine ring system via an intramolecular Heck reaction. Synlett. 2000; 8:1163-5. https://doi.org/10.1055/s-2000-6735
Parsons PJ, Charles MD, Harvey DM, Sumoreeah LR, Shell A, Spoors G, et al. A general approach to the galanthamine ring system. Tetrahedron Lett. 2001; 42(11):2209-11. https://doi.org/10.1016/S0040-4039(01)00111-3
Gibson (née Thomas) SE, Middleton RJ. The intramolecular Heck reaction. Contemp Org Synth. 1996; 3(6):447-71. https://doi.org/10.1039/CO9960300447
A. S, P. S, N. M, E. B, M. M, F. O, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with alzheimers disease: A prospective, observational study. CNS Drugs [Internet]. 2010; 24(2):163-76. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed9&NEWS=N&AN=2010061357 https://doi.org/10.2165/11310960-000000000-00000
Geldmacher DS, Whitehouse PJ. Differential diagnosis of Alzheimer's disease. Neurology. 1997; 48(5 SUPPL. 6). https://doi.org/10.1212/WNL.48.5_Suppl_6.2S
Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. FEBS Lett. 1999; 463(3):321-6. https://doi.org/10.1016/S0014-5793(99)01637-3
Farlow MR. Clinical Pharmacokinetics of Galantamine. Clin Pharmacokinet. 2003; 42(15):1383-92. https://doi.org/10.2165/00003088-200342150-00005
Gusztony G, Cervos-Navarro J, Bickel U, Kewitz H. Inhibition of Acetylcholinesterase Activity in Human Brain Tissue and Erythrocytes by Galanthamine, Physostigmine and Tacrine. Clin Chem Lab Med. 1991; 29(8):487-92. https://doi.org/10.1515/cclm.1991.29.8.487
Thomsen T, Bickel U, Fischer JP, Kewitz H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol. 1990; 39(6):603-5. https://doi.org/10.1007/BF00316106
Thomsen T, Zendeh B, Fischer JP, Kewitz H. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem Pharmacol. 1991; 41(1):139-41. https://doi.org/10.1016/0006-2952(91)90022-W
Storch A, Schrattenholz A, Cooper JC, Ghani EMA, Gutbrod O, Weber KH, et al. Physostigmine, galanthamine and codeine act as "noncompetitive nicotinic receptor agonists" on clonal rat pheochromocytoma cells. Eur J Pharmacol Mol Pharmacol. 1995; 290(3):207-19. https://doi.org/10.1016/0922-4106(95)00080-1
Schröder B, Reinhardt-Maelicke S, Schrattenholz A, McLane KE, Kretschmer A, Conti-Tronconi BM, et al. Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor α-polypeptide. J Biol Chem. 1994; 269(14):10407-16. https://doi.org/10.1016/S0021-9258(17)34075-9
Sweeney JE, Puttfarcken PS, Coyle JT. Galanthamine, an acetylcholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice. Pharmacol Biochem Behav. 1989; 34(1):129-37. https://doi.org/10.1016/0091-3057(89)90364-X
Irwin RL, Smith HJ. Cholinesterase inhibition by galanthamine and lycoramine. Biochem Pharmacol. 1960; 3(2):147-8. https://doi.org/10.1016/0006-2952(60)90030-7
Lilienfeld S. Galantamine - A novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002; 8(2):159-76. https://doi.org/10.1111/j.1527-3458.2002.tb00221.x
Fishkin RJ, Ince ES, Carlezon WA, Dunn RW. D-Cycloserine Attenuates Scopolamine-Induced Learning and Memory Deficits in Rats. Behav Neural Biol. 1993; 59(2):150-7. https://doi.org/10.1016/0163-1047(93)90886-M
Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001; 57(4):613-20. https://doi.org/10.1212/WNL.57.4.613
Belluardo N, Mudò G, Blum M, Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res. 2000; 113(1-2):21-34. https://doi.org/10.1016/S0166-4328(00)00197-2
Donnelly-Roberts DL, Xue IC, Arneric SP, Sullivan JP. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res. 1996; 719(1-2):36-44. https://doi.org/10.1016/0006-8993(96)00063-7
Yamashita H, Nakamura S. Nicotine rescues PC12 cells from death induced by nerve growth factor deprivation. 1996; 213:145-7. https://doi.org/10.1016/0304-3940(96)12829-9
Shimohama S, Greenwald DL, Shafron DH, Akaika A, Maeda T, Kaneko S, et al. Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res. 1998; 779(1-2):359-63. https://doi.org/10.1016/S0006-8993(97)00194-7
Wang HY, Lee DHS, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. β-Amyloid1-42 binds to α7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem [Internet]. 2000; 275(8):5626-32. https://doi.org/10.1074/jbc.275.8.5626
Nakamizo T, Kawamata J, Yamashita H, Kanki R, Kihara T, Sawada H, et al. Stimulation of nicotinic acetylcholine receptors protects motor neurons. Biochem Biophys Res Commun. 2005; 330(4):1285-9. https://doi.org/10.1016/j.bbrc.2005.03.115
Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, et al. Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity. Biochem Biophys Res Commun. 2004; 325(3):976-82. https://doi.org/10.1016/j.bbrc.2004.10.132
Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun [Internet]. 2009; 23(1):41-5. https://doi.org/10.1016/j.bbi.2008.06.011
Marrero MB, Lucas R, Salet C, Hauser TA, Mazurov A, Lippiello PM, et al. An α7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J Pharmacol Exp Ther. 2010; 332(1):173-80. https://doi.org/10.1124/jpet.109.154633
Amori RE, Lau J PA. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007; 298(2):194-206. https://doi.org/10.1001/jama.298.2.194
Geronikolou SA, Albanopoulos K, Chrousos G, Cokkinos D. Evaluating the homeostasis assessment model insulin resistance and the cardiac autonomic system in bariatric surgery patients: A meta-analysis. Adv Exp Med Biol. 2017; 988:249-59. https://doi.org/10.1007/978-3-319-56246-9_20
Taşçılar ME, Yokuşoğlu M, Boyraz M, Baysan O, Köz C, Dündaröz R. Cardiac Autonomic Functions in Obese Children - Original Article. J Clin Res Pediatr Endocrinol. 2011; 3(2):60-4. https://doi.org/10.4274/jcrpe.v3i2.13
Das UN. Vagus nerve stimulation as a strategy to prevent and manage metabolic syndrome. Med Hypotheses [Internet]. 2011; 76(3):429-33. https://doi.org/10.1016/j.mehy.2010.11.013
Abiola M, Favier M, Christodoulou-Vafeiadou E, Pichard AL, Martelly I, Guillet-Deniau I. Activation of Wnt/β-catenin signaling increases insulin sensitivity through a reciprocal regulation of Wnt10B and SREBP-1c in skeletal muscle cells. PLoS One. 2009; 4(12):1-14. https://doi.org/10.1371/journal.pone.0008509
Jojo GM, Kuppusamy G, Selvaraj K, Baruah UK. Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with excisting diabetic drugs. J Diabetes Metab Disord. 2019; 18(1):229-42. https://doi.org/10.1007/s40200-019-00405-2
Mezeiova E, Spilovska K, Nepovimova E, Gorecki L, Soukup O, Dolezal R, et al. Profiling donepezil template into multipotent hybrids with antioxidant properties. J Enzyme Inhib Med Chem [Internet]. 2018; 33(1):583-606. https://doi.org/10.1080/14756366.2018.1443326
Traykova M, Traykov T, Hadjimitova V, Krikorian K, Bojadgieva N. Antioxidant properties of galantamine hydrobromide. Zeitschrift fur Naturforsch - Sect C J Biosci. 2003; 58(5-6):361-5. https://doi.org/10.1515/znc-2003-5-613
Benchekroun M, Ismaili L, Pudlo M, Luzet V, Gharbi T, Refouvelet B, et al. Donepezil-ferulic acid hybrids as anti-Alzheimer drugs. Future Med Chem. 2015; 7(1):15-21. https://doi.org/10.4155/fmc.14.148
Brodaty H, Woodward M, Boundy K, Barnes N, Allen G. A naturalistic study of galantamine for Alzheimer's disease. CNS Drugs. 2006; 20(11):935-43. https://doi.org/10.2165/00023210-200620110-00006
Akilo OD, Kumar P, Choonara YE, Pradeep P, du Toit LC, Pillay V. Hypothesis: apo-lactoferrin-Galantamine Proteo-alkaloid Conjugate for Alzheimer's disease Intervention. J Cell Mol Med. 2018; 22(3):1957-63. https://doi.org/10.1111/jcmm.13484
Vidoni ED, Clutton J, Becker AM, Sherry E, Bothwell R MJ. Trial of oxaloacetate in alzheimer's disease (toad): Interim fdg pet analysis. Alzheimer's Dement J Alzheimer's Assoc. 2018; 14(7):P1435-6. https://doi.org/10.1016/j.jalz.2018.06.2411
Kowal NM, Ahring PK, Liao VWY, Indurti DC, Harvey BS, O'Connor SM, et al. Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors. Br J Pharmacol. 2018; 175(14):2911-25. https://doi.org/10.1111/bph.14329
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging [Internet]. 2008;3(January):456-67. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2546466&tool=pmcentrez&rendertype=abstract
Fisher AA, Davis MW. Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother. 2008; 42(2):278-83.
https://doi.org/10.1345/aph.1K514
Prvulovic D, Hampel H, Pantel J. Galantamine for Alzheimer ' s disease ( Review ). Expert Opin Drug Metab Toxicol. 2010; 4:345-54. https://doi.org/10.1517/17425251003592137
Diab M, Coloe J, Bechtel MA. Bullous pemphigoid precipitated by galantamine hydrobromide. Cutis. 2009; 83(3):139-40.
parallel-group 6-month study." Clinical therapeutics 28.3 (2006): 365-372 Dunbar Fiona Young Zhu and H. Robert Brashear. "Post hoc comparison of daily rates of nausea and vomiting with once-and twice-daily galantamine from a double-blind placebo-controlled. Post Hoc Comparison of Daily Rates of Nausea and Vomiting with Once- and Twice-Daily Galantamine from a Double-. 2006; https://doi.org/10.1016/j.clinthera.2006.03.002
Scott LJ, Goa KL, Giacobini E, Medical G, Mcdowell FH, Masterton W, et al. A Review of its Use in Alzheimer ' s Disease. Adis Drug Eval. 2000; 60(5):1095-122. https://doi.org/10.2165/00003495-200060050-00008
Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001; 71(5):589-95. https://doi.org/10.1136/jnnp.71.5.589
Published
Abstract Display: 1027 
PDF Downloads: 837 PDF Downloads: 214 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.